Details of the Drug

General Information of Drug (ID: DMHT34O)

Drug Name
Gemifloxacin
Synonyms
Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 389.4
Topological Polar Surface Area (xlogp) -0.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Bioavailability
The bioavailability of drug is 71% [2]
Clearance
The renal clearance of drug is 11.6 +/- 3.9 L/h [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 +/- 2 hours [4]
Metabolism
The drug is metabolized via the liver [2]
Unbound Fraction
The unbound fraction of drug in plasma is 0.3% [4]
Vd
The volume of distribution (Vd) of drug is 1.66-12.12 L/kg [3]
Chemical Identifiers
Formula
C18H20FN5O4
IUPAC Name
7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
Canonical SMILES
CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
InChIKey
ZRCVYEYHRGVLOC-HYARGMPZSA-N
Cross-matching ID
PubChem CID
9571107
ChEBI ID
CHEBI:101853
CAS Number
175463-14-6
DrugBank ID
DB01155
TTD ID
D0VR7W
VARIDT ID
DR00688
ACDINA ID
D00301

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [5]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Gemifloxacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Clarithromycin. Bacterial infection [1A00-1C4Z] [23]
Coadministration of a Drug Treating the Disease Different from Gemifloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [24]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [23]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Arn-509. Acute myeloid leukaemia [2A60] [25]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [26]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Oliceridine. Acute pain [MG31] [23]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Ivabradine. Angina pectoris [BA40] [25]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Bepridil. Angina pectoris [BA40] [27]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Dronedarone. Angina pectoris [BA40] [28]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Cilostazol. Arterial occlusive disease [BD40] [23]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Posaconazole. Aspergillosis [1F20] [23]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Levalbuterol. Asthma [CA23] [29]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Pirbuterol. Asthma [CA23] [30]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [25]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Retigabine. Behcet disease [4A62] [23]
Lomustine DMMWSUL Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [31]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Eribulin. Breast cancer [2C60-2C6Y] [28]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [23]
Thiotepa DMIZKOP Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [31]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Bosutinib. Breast cancer [2C60-2C6Y] [23]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [32]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [30]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [29]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [30]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [30]
Mestranol DMG3F94 Moderate Decreased absorption of Gemifloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [33]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Halothane. Corneal disease [9A76-9A78] [23]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Sevoflurane. Corneal disease [9A76-9A78] [28]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Probucol. Coronary atherosclerosis [BA80] [23]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Pasireotide. Cushing syndrome [5A70] [28]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Osilodrostat. Cushing syndrome [5A70] [25]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Escitalopram. Depression [6A70-6A7Z] [28]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Clomipramine. Depression [6A70-6A7Z] [23]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [28]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Gemifloxacin and Deutetrabenazine. Dystonic disorder [8A02] [34]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Ingrezza. Dystonic disorder [8A02] [35]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Solifenacin. Functional bladder disorder [GC50] [23]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [23]
Procarbazine DMIK367 Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [31]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [36]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [28]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [23]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [28]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Phenolphthalein. Irritable bowel syndrome [DD91] [28]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Crizotinib. Lung cancer [2C25] [38]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Ceritinib. Lung cancer [2C25] [28]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [31]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Osimertinib. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Selpercatinib. Lung cancer [2C25] [25]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Lumefantrine. Malaria [1F40-1F45] [40]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Halofantrine. Malaria [1F40-1F45] [41]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [42]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [25]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [43]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Vemurafenib. Melanoma [2C30] [28]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and LGX818. Melanoma [2C30] [44]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Gemifloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [28]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Panobinostat. Multiple myeloma [2A83] [45]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Siponimod. Multiple sclerosis [8A40] [40]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Fingolimod. Multiple sclerosis [8A40] [28]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Gemifloxacin and Ozanimod. Multiple sclerosis [8A40] [46]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Deflazacort. Muscular dystrophy [8C70] [47]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Romidepsin. Mycosis fungoides [2B01] [23]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Nilotinib. Myeloproliferative neoplasm [2A20] [28]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [23]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Gemifloxacin and Bupropion. Nicotine use disorder [6C4A] [48]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Entrectinib. Non-small cell lung cancer [2C25] [40]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Levomethadyl Acetate. Opioid use disorder [6C43] [25]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Lofexidine. Opioid use disorder [6C43] [28]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Rucaparib. Ovarian cancer [2C73] [23]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Triclabendazole. Parasitic worm infestation [1F90] [23]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Pimavanserin. Parkinsonism [8A00] [49]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [50]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Lefamulin. Pneumonia [CA40] [51]
Choline salicylate DM8P137 Moderate Additive CNS depression effects by the combination of Gemifloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [52]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Degarelix. Prostate cancer [2C82] [25]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and ABIRATERONE. Prostate cancer [2C82] [25]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Enzalutamide. Prostate cancer [2C82] [25]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Relugolix. Prostate cancer [2C82] [25]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Levomepromazine. Psychotic disorder [6A20-6A25] [23]
Salsalate DM13P4C Moderate Additive CNS depression effects by the combination of Gemifloxacin and Salsalate. Rheumatoid arthritis [FA20] [52]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Gemifloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [47]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Quetiapine. Schizophrenia [6A20] [28]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Aripiprazole. Schizophrenia [6A20] [40]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Iloperidone. Schizophrenia [6A20] [28]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Amisulpride. Schizophrenia [6A20] [53]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Asenapine. Schizophrenia [6A20] [28]
Ifosfamide DMCT3I8 Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [31]
Docetaxel DMDI269 Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [31]
Mitoxantrone DMM39BF Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [31]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [23]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [28]
Taxol DMUOT9V Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [31]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Pitolisant. Somnolence [MG42] [25]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [23]
Plicamycin DM7C8YV Minor Decreased absorption of Gemifloxacin due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [31]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Lenvatinib. Thyroid cancer [2D10] [23]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Gemifloxacin and Cabozantinib. Thyroid cancer [2D10] [25]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [23]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [23]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Gemifloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [23]
⏷ Show the Full List of 101 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Gemifloxacin 320 mg tablet 320 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
7 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
8 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
9 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
10 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
11 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
12 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
13 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
14 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
15 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
16 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
17 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
18 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
19 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
20 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
21 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
22 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
23 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
24 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
25 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
27 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
28 Canadian Pharmacists Association.
29 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
30 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
32 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
34 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
35 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
36 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
37 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
38 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
40 Cerner Multum, Inc. "Australian Product Information.".
41 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
42 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
43 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
44 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
45 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
47 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
48 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
49 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
50 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
51 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
53 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.